|
Characteristics
|
Items
|
N (%)
|
|---|
|
Sex
|
Female
|
26 (18.4%)
|
| |
Male
|
112 (79.4%)
|
|
Age
|
Mean
|
64
|
| |
Median (range)
|
66 (30–87)
|
| |
St.dev
|
11
|
|
Portal Vein Thrombosis
|
No
|
64 (46.4%)
|
| |
Yes
|
74 (53.6%)
|
|
Tumor location
|
Right lobe
|
57 (41.3%)
|
| |
Left lobe
|
10 (7.2%)
|
| |
Bilateral lobe
|
71 (51.4%)
|
|
Stage T
|
T1
|
8 (5.8%)
|
| |
T2
|
10 (7.2%)
|
| |
T3
|
120 (86.9%)
|
|
Stage N
|
N0
|
114 (82.60%)
|
| |
N1
|
24 (17.4%)
|
|
Stage M
|
M0
|
116 (84.1%)
|
| |
M1
|
22 (15.9%)
|
|
AJCC Stage
|
I
|
7 (5.1%)
|
| |
II
|
9 (6.5%)
|
| |
III
|
83 (60.1%)
|
| |
IV
|
39 (28.3%)
|
|
Okuda Stage
|
I
|
31 (22.4%)
|
| |
II
|
107 (77.6%)
|
|
BCLC Stage
|
A
|
9 (6.5%)
|
| |
B
|
29 (21.0%)
|
| |
C
|
100 (72.5%)
|
|
Child-Pugh Stage
|
A
|
96 (69.6%)
|
| |
B
|
42 (30.4%)
|
|
Hepatitis
|
No
|
19 (13.8%)
|
| |
B
|
71 (51.4%)
|
| |
C
|
43 (31.2%)
|
| |
B and C
|
5 (3.6%)
|
|
Initial Alpha-fetoprotein (?g/L)
|
Median (range)
|
11481 (2.4 – >58300)
|
|
Initial white blood count (kU/?L)
|
Median (range)
|
5.9 (2.7 – 15.6)
|
|
Initial haemoglobin level (g/dL)
|
Median (range)
|
12.8 (7.0 – 19.0)
|
|
Initial GPT level (U/L)
|
Median (range)
|
50.0 (8.8 – 396.0)
|
|
Initial total bilirubin level (mg/dL)
|
Median (range)
|
0.9 (0.3 – 8.5)
|
|
Initial tumor volume (cm3)
|
Median (range)
|
516 (28 – 3621)
|
|
Total liver volume (cm3)
|
Median (range)
|
1587 (548 – 5489)
|
|
Dose prescription
|
45Gy
|
16 (11.6%)
|
| |
60Gy
|
114 (82.6%)
|
| |
66Gy
|
8 (5.8%)
|
- Values refer to number of patients, % to the total number of 138 patients.
- AJCC: American joint Committee on Cancer, BCLC: Barcelona Clinic Liver Cancer. HCC: hepatocellular carcinoma. TACE: transarterial chemo-embolisation. RFA: radio-frequency ablation. GPT: Glutamic Pyruvic Transaminase.
